The Prevalence and Prognostic Relevance of ABO/Rh Blood Groups in Metastatic Breast Cancer Patients Undergoing Cyclin-Dependent Kinase 4/6 Inhibitors Therapy
Goncagul Akdag1, Akif Dogan1, Sedat Yildirim1, Oguzcan Kinikoglu1, Emre Kudu2, Heves Surmeli1, Deniz Isik1, Ozlem Nuray Sever1, Hatice Odabas1, Mahmt Emre Yildirim1, Nedim Turan11Department of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, İstanbul, Türkiye, 2Department of Emergency Medicine, Marmara University Pendik Training and Research Hospital, İstanbul, Türkiye
Objectives: Breast cancer (BC) is the most commonly malignancy in women. The emergence of cyclin-dependent ki nase inhibitors (CdK 4/6i) has significantly improved prognosis. Until now, no predictive factor of response to CdK4/6i has been identified. This study investigates the relationship between ABO and Rhesus (D) groups and the therapeutic response to CdK4/6i. Methods: This retrospective study registered records of mBC treated with CdK 4/6i at the Kartal Dr. Lutfi Kirdar City Hospital. Results: The study comprised 185 metastatic BC patients. During the study period, 32 patients (17.3%) died. The me dian overall survival (OS) was 18.3 months. The A group had the highest number of deaths (n=16), while the B group had the highest death rate proportionally (23.0%). Interestingly, no deaths were observed in the AB group. Disease progression was observed in 84 patients (45.4%). An analysis of the average progression-free survival (PFS) showed that patients with group O was PFS of 37.8 months (95% Confidence Interval (CI): 31.0-44.6), group A was 19.7 months (95% CI: 16.6-22.8), group B was 19.6 months (95% CI: 14.3-24.8), and group AB was 14.2 months (95% CI: 28.5-36.8). No statistically significant difference was observed when an OS (p=0.23) and PFS (p=0.138) analysis was performed ac cording to ABO groups. In the univariate analysis, the Rh factor did not serve as a prognostic factor on either PFS or OS. Conclusion: We found no prognostic effect of blood group or Rh status on overall survival and progression-free sur vival in patients. Keywords: Cyclin-dependent kinase inhibitors (CdK 4/6i), ABO blood and Rhesus (D) groups ,Oveall Survival, Progres sion Free Survival
Cite This Article
Akdag G, Dogan A, Yildirim S, Kinikoglu O, Kudu E, Surmeli H, Isik D, Sever O, Odabas H, Yildirim M, Turan N. The Prevalence and Prognostic Relevance of ABO/Rh Blood Groups in Metastatic Breast Cancer Patients Undergoing Cyclin-Dependent Kinase 4/6 Inhibitors Therapy. EJMI. 2024; 8(3): 212-219
Corresponding Author: Goncagul Akdag